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Abstract
Importance: Reporting of adverse events (AEs) following vaccination can help identify rare or 
unexpected complications of immunizations and aid in characterizing potential vaccine safety 
signals.
Objective: To create an electronic health record (EHR) module to assist clinicians with AE 
detection and reporting.
Design: We developed an open-source, generalizable clinical decision system called Electronic 
Support for Public Health–Vaccine Adverse Event Reporting System (ESP-VAERS) to facilitate 
automated AE detection and reporting using EHRs. ESP-VAERS prospectively monitors patients’ 
electronic records for new diagnoses, changes in laboratory values and new allergies for up to 6 
weeks following vaccinations. When suggestive events are found, ESP-VAERS sends a secure 
electronic message to the patient’s clinician. The clinician is invited to affirm or refute the event, 
add comments, and if they wish, submit an automated, pre-populated electronic case report to the 
national VAERS. High probability AEs following vaccination are reported automatically even if 
the clinician does not respond.
Setting: We implemented ESP-VAERS in December 2012 at the MetroHealth System, an 
inpatient and outpatient integrated healthcare system in Ohio with nearly 1 million encounters per 
year. We queried the VAERS database to determine MetroHealth’s baseline reporting rates from 
1/2009–3/2012 and then assessed changes in reporting rates with ESP-VAERS.
Participants: All patients receiving vaccinations between 12/04/2012 and 08/03/2013 and their 
clinicians.
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Exposure: ESP-VAERS
Main outcome and measure: The odds ratio of a VAERS report submission during the 
intervention period compared to the comparable pre-intervention period.
Results: In the 8 months following implementation, 91,622 vaccinations were given. ESP-
VAERS sent 1,385 messages to responsible clinicians describing potential AEs (15 per 1000 
vaccinations, mean 0.4 alerts per clinician per month (range 0–8)). Clinicians reviewed 1,304 
(94%) messages, responded to 209 (15%), and confirmed 16 for transmission to VAERS. An 
additional 16 high probability AEs were sent automatically. Reported events included seizure, 
pleural effusion, and lymphocytopenia. The odds of a VAERS report submission during the pilot 
period were 30.2 (95% CI, 9.52–95.5) times greater than the odds during the comparable pre-pilot 
period.
Conclusion and relevance: An open-source EHR-based clinical decision support system can 
increase AE detection and reporting rates in VAERS.
Introduction
Routine vaccination is a cornerstone of preventive healthcare. Vaccines have dramatically 
decreased the incidence of many serious infectious diseases.1 While pre-licensure clinical 
trials are helpful to characterize the basic safety profile of vaccines, rare adverse events 
(AEs) may only become apparent after widespread use in the community. To this end, 
rigorous post-marketing vaccine safety surveillance is critical to building public and 
professional trust in vaccines.
The Centers for Disease Control and Prevention (CDC) and the US Food and Drug 
Administration (FDA) jointly operate the Vaccine Adverse Event Reporting System 
(VAERS). VAERS is a passive reporting system that accepts spontaneous AE reports from 
clinicians, pharmaceutical companies, and the public. VAERS reports vary in quality and 
completeness and under-reporting, especially of mild and self-limiting AEs, appears 
common.2,3 Reasons for clinician under-reporting might include failure to associate an acute 
health event to recent vaccines, lack of awareness of VAERS, the misperception that only 
serious events should be reported, or lack of time to report. VAERS reports often lack 
critical data such as vaccine lot numbers and the precise date of vaccination.4 Currently, no 
widespread, automated mechanisms exist to facilitate detection and electronic reporting of 
AEs to VAERS by clinicians. Consequently, the utility of VAERS data is diminished by 
substantial under-reporting and sparse documentation of patients’ clinical status and 
potential explanations of their conditions.2,5
One potential adjunct is to take advantage of the increasing penetration and functionality of 
electronic health record (EHR) systems. Adding surveillance and AE reporting capacity to 
EHRs offers a practical and efficient means to monitor large numbers of patients, integrate 
AE reporting into physicians’ workflow, elicit clinician comments in a timely manner, and 
efficiently submit reports. We describe the development and implementation of an EHR-
based AE detection and reporting system called Electronic Support for Public Health–
Vaccine Adverse Event Reporting System (ESP-VAERS) that builds upon an automated 
vaccine AE surveillance system based in an ambulatory electronic medical record.4 ESP-
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VAERS identifies possible AEs following vaccination, prompts clinicians for input when 
appropriate, and has the capability to submit secure electronic reports to VAERS. The ESP-
VAERS design is open-source and compatible with any modern EHR system.
Methods
Study setting
ESP-VAERS was implemented in the MetroHealth System, a tertiary care academic health 
system in northeast Ohio that provides a full range of inpatient and outpatient primary and 
specialty care services and has a network of community health centers that primarily focus 
on primary care and preventive health services. The MetroHealth system includes >400 
primary care and specialty care physicians and 373,000 established patients with nearly 1 
million medical encounters per year. Both the academic medical center and the community 
provider network are served by an integrated EpicCare EHR system.6 All adult and pediatric 
patients served by MetroHealth were included in the study.
MetroHealth utilizes the Electronic Support for Public Health network (ESPnet) public 
health surveillance platform.7 ESPnet is open-source software that facilitates automated 
detection and reporting from EHRs to health departments.8,9 ESPnet is populated nightly 
with structured data from all patients seen throughout the healthcare system within the 
preceding 24 hours. These data include demographics, diagnoses, laboratory reports, 
prescriptions, and vaccines. ESPnet organizes these data into tables, applies algorithms to 
detect events of public health interest, and when appropriate, sends electronic case reports to 
the state health department. MetroHealth has been using ESPnet for automated notifiable 
disease surveillance and electronic reporting to the Ohio Department of Health since 2009.10
Development of ESP-VAERS
We developed a new ESPnet module, ESP-VAERS, to monitor patients’ EHRs for 42 days 
following each vaccination for possible new onset AEs. ESP-VAERS identifies every 
vaccine administered and prospectively records the patient’s new diagnostic codes, 
laboratory tests, allergy lists, and medication prescriptions during the 6-week surveillance 
period. We developed and applied algorithms designed to detect both expected and 
unexpected AEs. When a possible AE is identified based on the algorithms, it is recorded in 
a registry database table and the clinician is securely messaged electronically through the 
EHR to consider if the event should be reported to VAERS (Figure 1).
Algorithm development
We divided ICD-9 diagnosis codes into 3 categories: 1) codes for severe and/or potential 
high probability diagnoses that have previously been associated with vaccines,11,12 2) codes 
for diagnoses of undetermined significance that could conceivably be associated vaccines, 
and 3) codes for diagnoses that are not associated with receipt of vaccines (e.g., well child 
visits, fractures, etc.) (Appendix). Category 1 included ICD-9 codes for severe and potential 
high probability diagnoses included in the VAERS Table of Reportable Events Following 
Vaccination11 and the Vaccine Injury Table12 and ICD-9 codes defined as immunization 
reactions. The onset intervals and exclusion criteria for each diagnosis were based on the 
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VAERS Table of Reportable Events Following Vaccination.11 Category 2 included all ICD-9 
codes other than the potential high probability and severe event codes in Category 1, the 
extremely low probability codes in Category 3, and any codes present in the individual 
patient’s record within the preceding 36 months. Onset intervals and additional exclusion 
criteria for these codes were based on clinical expertise, literature review, and review of 
alerts using retrospective and pilot project data. Codes for routine care and diagnoses very 
unlikely to represent AEs following vaccination were placed into Category 3 and did not 
trigger an alert.
We assessed for significant changes in key laboratory tests following vaccination including 
hemoglobin, white blood cell count, platelet count, creatinine, alanine aminotransferase, 
aspartate transaminase, alkaline phosphatase, bilirubin, sodium, potassium, calcium, 
creatinine kinase and partial thromboplastin time. We set different thresholds for significant 
changes for each laboratory test (Appendix). In general, a significant change was defined as 
substantial worsening compared to the patient’s most recent test result or an abnormal result 
without a prior record of any results since ESP’s inception on January 1, 2009. ESP also 
followed the patient’s coded allergy list for 30 days after vaccination. The appearance of a 
new allergy to the index vaccine was considered suggestive of an adverse event.
Possible AE messages were sent to clinicians’ Epic InBasket, a secured system for clinicians 
to communicate with one another regarding patient care within the EHR.6 Each message 
contained a brief summary of the patient, the vaccination and the suspected AE, and a 
hyperlink to a web form with more information. Selecting the hyperlink opened a web form 
with details about the vaccination, adverse event, and options to approve and send the 
notification to VAERS with optional comments or cancel the notification and add optional 
comments. The hyperlink also included 3 questions about the utility and acceptability of the 
message:
1. Was this message helpful? (Yes/No)
2. Did it interrupt your workflow? (Yes/No)
3. Has the number of messages recently been Appropriate or Too Frequent?
Reports of severe and potential high probability AEs following vaccination, such as 
anaphylaxis and encephalitis, were submitted automatically even if the clinician did not 
respond. Reports sent to VAERS included patient’s demographics, vaccine, lot number, date 
of vaccination, possible adverse event, date of adverse event, and any free-text comments 
provided by clinicians. If multiple vaccines were given simultaneously, information on all 
vaccines were included in the report as per the standard VAERS protocol.13 Cases approved 
for transmission were sent to VAERS as HL7 version 2.3.1 messages using CDC’s PHIN-
MS secure messaging protocol.14
Following implementation and testing by co-investigators and clinician collaborators, 
MetroHealth clinicians were offered a brief training session to ensure that they were familiar 
with the project and comfortable managing the notifications. Support for clinicians using the 
ESP-VAERS system was provided through handouts, teaching sessions, and an EHR 
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message to all clinicians. The ESP-VAERS study period ran from December, 04, 2012, the 
date that the system was implemented in all MetroHealth practices, to August 03, 2013.
Historical reports
We queried the VAERS database for all reports sent from the state of Ohio from January 01, 
2009 to March 31, 2012, limiting the search to reports sent from December 4th -August 3rd 
in each year to match the study period. Based on the city, the name of the clinic or hospital, 
the address of the clinic or hospital and/or the provider name, we identified reports sent from 
the MetroHealth System and verified these reports in the EHR. The number of vaccinations 
in the historical period was determined by running ESP-VAERS on all MetroHealth data 
from January 01, 2009 to August 03, 2009, December 04, 2009 to August 03, 2010, 
December 04, 2010 to August 03, 2011, and December 04, 2011 to March 31, 2012.
Statistical analysis
Using logistic regression, we compared the odds of a VAERS report after vaccination in the 
pilot period to the odds of a report in the historical period. We controlled for the time of year 
by restricting the historical reports to the period of calendar time relevant to the pilot.
The study was approved by the Institutional Review Boards of the MetroHealth System and 
Harvard Pilgrim Health Care Institute. We employed best-practice methods to ensure web 
application security, strong message encryption, and other techniques to ensure that these 
data were protected at or beyond standards set by the American National Standards Institute 
Healthcare Information Technology Standards Panel.15,16
Results
During the 8-month study period, 91,622 vaccinations were administered. The most 
common vaccines given were the combined tetanus, diphtheria and pertussis vaccine (Tdap) 
(15,279 doses) and the inactivated influenza vaccine (13,629 doses) (Table 1). ESP-VAERS 
sent 1,385 messages to responsible clinicians describing possible AEs following vaccination, 
corresponding to a rate of 15 messages per 1,000 vaccinations (Figure 2). The average 
number of alerts per clinician was 0.4 messages per month, and the range was between 0 and 
8 messages per month.
Clinicians opened 1,304 messages (94%), responded to 209 messages (15%), and confirmed 
16 for transmission of reports to VAERS (Table 2). The diagnoses for transmitted reports 
included seizure, eosinophilia, Bell’s palsy, pleural effusion, lymphocytopenia, leukopenia, 
cellulitis, febrile seizure, rash, viral exanthem, rubella symptoms, fever and mild 
neutropenia, fever and hypothyroidism. Of the 16 confirmed messages, 15 included custom 
comments from the healthcare provider. The remaining 193 alerts were designated by 
clinicians as not associated with the vaccination. The most common diagnoses, designated as 
not associated with the vaccination, included bronchospasm, nonspecific skin eruption, 
cellulitis, fever and seizure. These five diagnostic categories accounted for 22% of all of the 
alerts that were considered not associated with the vaccination.
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An additional 16 high probability AEs following vaccination were sent automatically (Table 
3). All of the high probability reports were coded by clinicians as immunization reactions. 
These included: possible allergic reaction, fever alone, fever and a local reaction, fever and 
rash, cellulitis and fussiness. Thus, 32 VAERS reports were sent for 91,622 vaccines over an 
8-month period for a net reporting rate of 34.9 VAERS reports per 100,000 vaccinations 
(Table 4).
Of the 1,160 alerts without a response and not automatically sent, the most common 
diagnoses included nonspecific skin eruptions, eosinophilia, seizure, fever, leukopenia and 
lymphocytopenia, accounting for 18% of the 1,160 alerts with no response.
We identified three reports in VAERS that were sent by MetroHealth clinicians from January 
01, 2009 to August 03, 2009, December 04, 2009 to August 03, 2010, December 04, 2010 to 
August 03, 2011, December 04, 2011 to March 31, 2012 prior to the inception of ESP-
VAERS. During this period, 274,080 vaccines were administered at MetroHealth 
corresponding to a reporting rate prior to initiation of the ESP-VAERS pilot of 1.09 reports 
per 100,000 vaccinations. The odds of a VAERS report submission during the study period 
were 30.2 (95% CI, 9.52–95.5) times greater than the odds during the comparable pre-
intervention period.
Many clinicians felt that the messages were helpful (115/209; 55%) and did not interrupt 
workflow (116/209; 56%). The majority of the clinicians (166/209; 79%) stated that the 
number of messages was appropriate.
Discussion
Our implementation of ESP-VAERS demonstrates that EHRs can facilitate identification of 
possible AEs following vaccination, engage clinicians within their existing workflows to 
comment on events, and generate and submit secure reports to VAERS. Implementation of 
ESP-VAERS was associated with a 30.2 fold increase in the odds of MetroHealth 
submission of AE reports to VAERS. Many reported AEs were medically significant, 
including seizure, lymphocytopenia and Bell’s palsy, and other AEs such as pleural 
effusions have only rarely been reported following vaccination.17 Such reporting might 
provide hypothesis generating information to CDC and FDA that results in further 
assessment of a possible association. We determined that an open-source EHR-based clinical 
decision support system improves the detection and reporting of AEs following vaccination.
Through this pilot, we developed new logic for automated identification of potential high 
probability and possible AEs following vaccination, we developed capacity for querying 
clinicians via the EHR from an external source, and we implemented automated secure HL7 
messaging to VAERS. Such a system is dependent upon clinician acceptance and 
participation. Many of the clinicians found that the messages were helpful and did not 
interrupt their workflow. Most found that the number of messages sent was appropriate.
EHRs offer an increasingly available opportunity for low cost monitoring and reporting of 
AEs. EHRs offer three potential advantages over existing claims based systems: 1) EHRs 
have access to much richer data streams, including vital signs and laboratory test results, 2) 
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EHR data streams are updated in near real-time, permitting more timely AE detection 
compared to claims databases, and 3) EHR systems can query patients’ clinical providers for 
comments on possible AEs in near-real time, adding richness and specificity to AE 
detection.
ESP-VAERS provides potential advantages over traditional passive reporting systems: ESP-
VAERS prompts clinicians to recognize possible AEs and automates components of the 
VAERS reporting process. Thus, the increased rate of VAERS report submission during the 
intervention period might be due to a combination of alerting clinicians to possible AEs that 
they may have otherwise missed or disregarded, notifying clinicians to consider reporting 
the AE to VAERS, and facilitating the report submission process. In addition, because they 
contain rich data on large numbers of patients, automated EHR surveillance systems can 
facilitate estimation of possible AE incidence densities in defined populations. In contrast, 
data from passive surveillance yields adverse event counts only for those reports submitted. 
Finally, ESP-VAERS reports can be pre-populated with information from the EHR, allowing 
for additional comments from a clinician, thus limiting the likelihood of reports with 
missing key data fields. This is in contrast to traditional passive VAERS reports which have 
been found to be missing essential variables including age, date of birth, vaccination date 
and date of adverse event onset.18 As ESP-VAERS is not embedded within an EHR system, 
but rather sits outside of the EHR, it does not burden routine EHR operations. Use of EHR 
systems is increasingly common, so a generalizable and portable automated AE surveillance 
approach based on existing EHR systems potentially offers a feasible solution to quickly 
ramp up AE surveillance to provide clinically rich reports at relatively low marginal cost.
Limitations to ESP-VAERS include the large number of alerts and the inter-related risk of 
clinician alert fatigue. Although clinicians opened 94% of the AE reports we sent, they only 
elected to respond to 15%. The current algorithm is restricted to single codes for new 
diagnoses and historical events. Increasing the sophistication of the algorithm and program 
to use combinations of ICD-9 codes and laboratories for diagnoses and exclusion criteria 
may reduce the number of false positive alerts that clinicians are receiving. Furthermore, the 
upgrade to ICD-10 may decrease the false positive alerts given the greater richness of 
ICD-10 codes for specific diagnoses compared to ICD-9 codes.19 Further investigation into 
the large number of alerts that lack a response is also warranted, including a better 
understanding of why some alerts were opened and some were not.
An open-source, EHR-diagnostic clinical decision support system with advanced predictive 
algorithms using ICD-9 codes, laboratory values, allergies and the potential for medication 
prescriptions can significantly improve the detection and reporting of AEs following 
vaccination to VAERS. This type of open-source, advanced clinical decision support system 
represents new opportunities for clinical decision support to improve public health.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Flowchart of possible vaccine related adverse events
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Figure 2. 
Flowchart of the vaccine related data from MetroHealth between December 04, 2012 and 
August 03, 2013
*93% of the messages opened
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Baker et al. Page 11
Table 1.
Vaccines administered at MetroHealth between December 04, 2012 and August 03, 2013
Vaccines Administered*
N = 91,622
Vaccine Count (%)
   Tdap 15,279 (17%)
   IIV 13,629 (15%)
   PCV13 7,561 (8%)
   Hib 7,051 (8%)
   Hepatitis A Pediatric 6,508 (7%)
   HPV 5,424 (6%)
   DTaP-Hepatitis B-IPV 5,099 (6%)
   PPSV23 4,230 (5%)
   Pentavalent rotavirus 3,087 (3%)
   Other 23,754 (26%)
Abbreviations: Tdap-combined tetanus, diphtheria and pertussis; IIV- inactivated influenza vaccine; PCV- pneumococcal conjugate vaccine; Hib-
haemophilus influenzae type B; HPV-human papillomavirus; DTaP- diphtheria, tetanus and pertussis; IPV-inactivated polio vaccine; PPSV- 
Pneumococcal polysaccharide vaccine.
*Some adverse events were counted against multiple vaccines if the patient received more than one vaccine at the index encounter.
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Table 2.
Clinician confirmed VAERS reports at MetroHealth between December 04, 2012 and August 03, 2013
VAERS Reports: Clinician Confirmed (n=16)
  Adverse Event   Vaccine(s) Administered
   Seizure    IIV
   Eosinophilia    IIV
   Eosinophilia    PCV13
   Bell’s palsy    Tdap
   Pleural effusion    IIV, Tdap
   Lymphocytopenia    Tdap
   Leukopenia    Tdap
   Cellulitis    DTaP-IPV, MMRV
   Febrile seizures, rash    MMR, Varicella
   Viral exanthem, rubella symptoms    DTaP, Hepatitis B, IPV, Hib, IIV, MMR, Varicella, PCV13
   Fever and mild neutropenia    PPSV23
   Rash    DTaP-IPV, MMRV
   Rash    Hepatitis A, Hib, MMR, PCV13, Varicella
   Rash    Hepatitis A, MMRV
   Fever    DTaP-HepB-IPV, Hib, PCV13, Rotavirus
   Hypothyroidism    Shingles, Tdap
Abbreviations: IIV- inactivated influenza vaccine; PCV- pneumococcal conjugate vaccine; Tdap- combined tetanus, diphtheria and pertussis; DTaP- 
diphtheria, tetanus and pertussis; IPV-inactivated polio vaccine; MMRV-measles, mumps, rubella and varicella; MMR-measles, mumps and rubella; 
PPSV- Pneumococcal polysaccharide vaccine; Hib- haemophilus influenzae type B.
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Table 3.
Automatically sent VAERS reports from MetroHealth between December 04, 2012 and August 03, 2013
VAERS Reports: Automatically Sent (n=16)
  ICD-9
Codes for   Adverse Event   Vaccine(s)
Immunization Reaction
  Reaction to vaccine - possible allergic reaction    IIV
  Fever, local immunization reaction    DTaP-IPV, MMRV
  Rash, fever    Hepatitis A, MMR, Varicella
  Rash, fever    Hepatitis A, MMR, Varicella
  Fever    DTaP-Hepatitis B-IPV, Hib, PCV13, Rotavirus
  Cellulitis    IIV, Meningococcal
  Fussiness    Hepatitis A, MMRV
  Local immunization reaction    DTaP-IPV, MMRV
  Local immunization reaction    DTaP-IPV, HepA, MMRV
  Local immunization reaction    Hepatitis A, MMR, Varicella
  Local immunization reaction    HPV, Meningococcal, Tdap
  Local immunization reaction    IIV
  Local immunization reaction    IIV, PPSV23, Tdap
  Local immunization reaction    PPSV23
  Local immunization reaction    Shingles
  Local immunization reaction    Tdap
Abbreviations: IIV- inactivated influenza vaccine; DTaP- diphtheria, tetanus and pertussis; IPV-inactivated polio vaccine; MMRV-measles, mumps, 
rubella and varicella; MMR-measles, mumps and rubella; Hib- haemophilus influenzae type B; PCV- pneumococcal conjugate vaccine; HPV-
human papillomavirus; Tdap-combined tetanus, diphtheria and pertussis; PPSV- Pneumococcal polysaccharide vaccine.
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Table 4.
VAERS reports sent from MetroHealth during the study period as compared to the pre-study period.
Results
MetroHealth
Data
VAERS
Reports
Time
period Reports/ Month Vaccinations
Reports/
Vaccination
Pre-pilot Data 3 27 months 0.11 report/ month 274,080 vaccines 1.09 reports/ 100,000 vaccines
Pilot Data 32 8 months 4 reports/ month 91,622 vaccines 34.9 reports/ 100,000 vaccines
Clin Infect Dis. Author manuscript; available in PMC 2019 July 21.
